Get the Stockscreener App
474.27
2.42%
-11.76
After Hours:
473.45
-0.82
-0.17%
Vertex Pharmaceuticals Inc stock is traded at $474.27, with a volume of 1.06M.
It is down -2.42% in the last 24 hours and up +1.86% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$486.03
Open:
$478.95
24h Volume:
1.06M
Relative Volume:
0.75
Market Cap:
$120.48B
Revenue:
$12.07B
Net Income/Loss:
$3.95B
P/E Ratio:
30.93
EPS:
15.3349
Net Cash Flow:
$3.19B
1W Performance:
-2.70%
1M Performance:
+1.86%
6M Performance:
+19.58%
1Y Performance:
-1.87%
1-Day Range:
$471.58
$484.10
1-Week Range:
$471.58
$498.02
52-Week Range:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-22-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-12-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-07-26 | Resumed | UBS | Buy |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex at TD Cowen Conference: Strategic Growth and Innovation By Investing.com - Investing.com India
Vertex Pharma Stock: Why Wall Street Is Quietly Buying the Dip - AD HOC NEWS
Victory Capital Management Inc. Buys 92,402 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer - GlobeNewswire Inc.
VRTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
American Century Companies Reduces Vertex Pharmaceuticals Stake - National Today
BMO Maintains Outperform on VRTX, Vertex Pharmaceuticals Incorporated Mar 2026 - Meyka
Joy Liu reports multiple share sales for VRTX (NASDAQ: VRTX) in Form 144 - Stock Titan
Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Vertex (VRTX) SVP & Chief Accounting Officer sells 357 shares in open-market trade - Stock Titan
Vertex Gets Rating Upgrade, Earnings Rose Every Quarter This Past Year - Investor's Business Daily
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - Yahoo Finance
111 Capital Invests $1.71 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Vertex Interest Renews CRISPR Therapeutics Takeover Talk And Investor Questions - simplywall.st
Vertex Pharmaceuticals Incorporated $VRTX Stock Holdings Lessened by US Bancorp DE - MarketBeat
Huntington National Bank Lowers Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
American Century Companies Inc. Lowers Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
CRISPR Therapeutics Takeover Chatter With Vertex Puts Investor Tradeoffs In Focus - simplywall.st
A Look At Vertex Pharmaceuticals (VRTX) Valuation As Shares Trade Near Vestra Fair Value Estimate - Yahoo Finance
Wealthedge Investment Advisors LLC Invests $965,000 in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Rafferty Asset Management LLC Purchases 6,020 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows High Technical and Setup Ratings for Potential Breakout - ChartMill
Andra AP fonden Acquires New Shares in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Here’s What Analysts Are Saying About Vertex Pharmaceuticals (VRTX) - Insider Monkey
VRTX (NASDAQ: VRTX) files Form 144 to sell 40,000 common shares - Stock Titan
Vertex Broadens Growth Story With Gene Editing And Non Opioid Pain Therapies - simplywall.st
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
Intech Investment Management LLC Has $13.46 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
TD Asset Management Inc Sells 247,634 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Erste Asset Management GmbH Has $26.69 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells 58,613 Shares of Stock - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Holdings Raised by Banco Santander S.A. - MarketBeat
Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells 1,846 Shares of Stock - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Ourania Tatsis Sells 260 Shares - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) CAO Kristen Ambrose Sells 223 Shares - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Mark Bunnage Sells 620 Shares - MarketBeat
Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells 4,910 Shares of Stock - MarketBeat
Vertex Pharmaceuticals EVP Sachdev sells $897k in shares By Investing.com - Investing.com Canada
Vertex Pharma EVP McKechnie sells $2.39m in shares By Investing.com - Investing.com Nigeria
Insider Sell: Jonathan Biller Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharma EVP McKechnie sells $2.39m in shares - Investing.com
Vertex Pharmaceuticals EVP Tatsis sells $126k in stock - Investing.com UK
Vertex Pharmaceuticals Incorporated : Statement of Changes in Beneficial Ownership (Form 4) - marketscreener.com
Vertex (VRTX) EVP Atkinson trades shares under Rule 10b5-1 plan - Stock Titan
Daiwa Securities Adjusts Vertex Pharmaceuticals PT to $561 From $500, Maintains Buy Rating - marketscreener.com
Vertex Pharma Stock: Is Wall Street Too Cautious After The Neuropathy Surprise? - AD HOC NEWS
Vertex Pharmaceutical uses MicroStrategy as a one-stop shop for business intelligence. - Strategy
Vertex Pharmaceuticals's Options: A Look at What the Big Money is Thinking - Benzinga
Vertex Pharmaceuticals (VRTX) Form 144 lists insider sales and restricted vesting - Stock Titan
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.05%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):